Coherus BioSciences (NASDAQ:CHRS) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $12.00 price target on the biotechnology company’s stock.

A number of other analysts also recently issued reports on CHRS. StockNews.com downgraded Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and cut their target price for the stock from $4.00 to $1.50 in a research note on Friday, August 16th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.13.

Coherus BioSciences Stock Down 0.6 %

Coherus BioSciences stock traded down $0.01 during mid-day trading on Thursday, hitting $0.82. 3,522,703 shares of the company were exchanged, compared to its average volume of 2,673,164. The company has a market capitalization of $93.90 million, a PE ratio of -10.19 and a beta of 0.69. Coherus BioSciences has a 1-year low of $0.66 and a 1-year high of $3.70. The business has a fifty day moving average of $1.01 and a 200 day moving average of $1.46.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to analyst estimates of $57.08 million. Research analysts expect that Coherus BioSciences will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Coherus BioSciences

A number of hedge funds have recently made changes to their positions in CHRS. Nisa Investment Advisors LLC grew its holdings in Coherus BioSciences by 2,672.8% during the second quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 19,912 shares during the period. TIAA Trust National Association purchased a new position in shares of Coherus BioSciences in the second quarter worth about $47,000. Bayesian Capital Management LP bought a new stake in shares of Coherus BioSciences in the first quarter valued at approximately $56,000. Price T Rowe Associates Inc. MD boosted its holdings in Coherus BioSciences by 32.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock worth $74,000 after buying an additional 7,608 shares during the period. Finally, Virtu Financial LLC purchased a new position in Coherus BioSciences in the 1st quarter valued at approximately $94,000. 72.82% of the stock is currently owned by institutional investors.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.